scholarly journals Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Pan-pan Liu ◽  
Yi Xia ◽  
Xi-wen Bi ◽  
Yu Wang ◽  
Peng Sun ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Survival Rates ◽  
Multivariable Analysis ◽  
B Cell Lymphoma ◽  
Treatment Modalities ◽  
Seer Database ◽  
Limited Information ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Treatment modalities for primary gastric diffuse large B-cell lymphoma (PG-DLBCL) have changed significantly during the past decades. However, limited information on the trends of clinical outcome of PG-DLBCL patients has been reported. Here, we conducted a retrospective analysis using the Surveillance, Epidemiology, and End Results (SEER) database to compare the survival trends of PG-DLBCL patients from 1973 to 2014. Patients were divided into 2 eras based on the year of diagnosis in relation to immunotherapy with the anti-CD20 antibody rituximab that was approved in 1997 and became a widely used drug in 2000. There was a significant improvement in survival among PG-DLBCL patients diagnosed in the 2001–2014 era (n=4186) compared to patients diagnosed in the 1973–2000 era (n=2865), with the 5-year overall survival rates of 53% and 47%, respectively (p=0.001). Multivariable analysis revealed that the 2001–2014 era (HR = 0.892, p=0.001) was associated with lower mortality and that patients of older age, Black race, advanced stage, and male gender were associated with poor prognosis. Although outcome of PG-DLBCL has significantly improved over time, more effective therapies are needed for older patients to further improve their survival.

Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B‐Cell Lymphoma

2021 ◽  
Author(s):  
Brandon M. Lehrich ◽  
Arash Abiri ◽  
Khodayar Goshtasbi ◽  
Jack Birkenbeuel ◽  
Tyler M. Yasaka ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Treatment Modalities ◽  
Survival Outcomes ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Metachronous Diffuse Large B-Cell Lymphoma of the Breasts: A Case Report and Literature Review

2021 ◽  
Vol 14 (6) ◽  
Author(s):  
Mastane Saneii ◽  
Pedram Fadavi ◽  
Kambiz Novin ◽  
Maryam Garousi
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Maximum Level ◽  
Treatment Modalities ◽  
Regional Lymph Nodes ◽  
Case Presentation ◽  
Large B Cell Lymphoma ◽  
One Year ◽  
Large B Cell

Introduction: PBL is a rare form of extranodal lymphoma. The most common pathology is diffuse large B cell lymphoma and most patients are diagnosed at stages 1 and 2. The therapeutic options undertaken so far include surgery, radiotherapy, and chemotherapy Case Presentation: The patient was a 54-year old woman with localized primary breast DLBCL. The patient underwent 6 courses of chemotherapy with an RCHOP regimen followed by radiotherapy of the breast and regional lymph nodes with a 40 Gy dose. The patient was in complete remission on PET scan 3 months later. Around one year after, the patient experienced relapse in the contralateral breast. Conclusions: In the pattern of relapse of patients, there is a tendency for extranodal relapse. In some studies maximum level of relapse occurring in CNS and some advocate CNS prophylaxis in these patients. The best outcome is for patients treated with chemotherapy including rituximab followed by radiation. We reviewed some studies in the aspect of treatment modalities and site of relapsed.

scholarly journals Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis

2018 ◽  
Vol 7 (5) ◽  
pp. 1845-1851 ◽  
Author(s):  
Pan-pan Liu ◽  
Ke-feng Wang ◽  
Jie-tian Jin ◽  
Xi-wen Bi ◽  
Peng Sun ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Seer Database ◽  
Database Analysis ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Significance of c-myc Rearrangements in Diffuse Large B-Cell Lymphoma.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2030-2030
Author(s):  
Philip Bierman ◽  
Fausto Loberiza ◽  
Bhavana Dave ◽  
Warren Sanger ◽  
R. Gregory Bociek ◽  
...  
Keyword(s):  
Overall Survival ◽  
B Cell ◽  
Cell Lymphoma ◽  
Survival Rates ◽  
Progression Free Survival ◽  
B Cell Lymphoma ◽  
Free Survival ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Overall Survival Rates

Abstract Rearrangements of the c-myc oncogene can be seen in 5–10% of patients with diffuse large B-cell lymphoma. However, studies examining the significance of this finding have yielded conflicting results. Therefore, we performed a retrospective analysis to determine the clinical significance of c-myc rearrangements in diffuse large B-cell lymphoma. The results of classical cytogenetic studies and FISH analyses were used to identify diffuse large B-cell lymphoma cases in the database of the Nebraska Lymphoma Study Group with or without c-myc rearrangements. Patients who were HIV positive and those with post-transplant lymphoproliferative disease were excluded. We identified 16 patients with diffuse large B-cell lymphoma and c-myc rearrangements. All patients were initially treated with doxorubicin- or mitoxantrone-containing chemotherapy regimens. The median age of these 16 patients was 61 years (range 40 to 80), and 5 (31%) were males. The International Prognostic Index (IPI) was 0–2 at diagnosis in 9 patients (56%), and 3–5 in 7 patients (44%). Eleven patients (69%) had bulky disease (≥ 5 cm) at diagnosis. No significant differences in outcome were identified when the 16 c-myc positive patients were compared with 97 c-myc negative diffuse large B-cell lymphoma patients in the same age range. The actuarial 5-year progression-free survival for the c-myc positive patients was 23% (95% CI 6% to 46%), as compared with 38% (95% CI 29% to 48%) for c-myc negative patients (p=0.17). The actuarial 5-year overall survival rates were 36% (95% CI 14% to 59%) and 47% (95% CI 36% to 56%), respectively (p=0.19). Classical cytogenetics and FISH analyses were also used to examine the 16 c-myc positive cases for bcl-2 rearrangements. Eight (50%) cases had rearrangements of bcl-2 in addition to c-myc rearrangements. These patients were similar to the c-myc positive/bcl-2 negative patients except for a higher likelihood of an elevated LDH level at diagnosis (88% vs. 25%; p=0.03). The actuarial 5-year progression-free survival for c-myc positive/bcl-2 positive patients was 0%, as compared to 33% (95% CI 6% to 66%) for patients with rearrangements of c-myc alone, and 37% (95% CI 28% to 47%) for c-myc negative patients. The actuarial 5-year overall survival rates were 12% (95% CI 1% to 42%), 47% (95% CI 12% to 76%), and 41% (95% CI 31% to 51%), respectively. A multivariate analysis, adjusting for IPI score, demonstrated that the relative risk (RR) of treatment failure was significantly worse for the c-myc positive/bcl-2 positive patients, as compared to the c-myc negative patients (RR 2.86, 95% CI 1.32–6.23; p=0.008). Similarly, mortality was also significantly worse for the c-myc positive/bcl-2 positive patients, as compared to the c-myc negative patients (RR 2.69, 95% CI 1.18–6.11; p=0.02). In contrast, no significant differences in treatment failure or overall survival were demonstrated when c-myc positive/bcl-2 negative patients were compared with c-myc negative patients. Our results demonstrate that the c-myc rearrangement is not associated with poorer survival in patients with diffuse large B-cell lymphoma. However, patients with rearrangements of bcl-2 in addition to c-myc had significantly worse progression-free survival and overall survival.

A Retrospective Study to Evaluate the Survival Rates in R-CHOP Chemotherapy Followed by Autologous Stem Cell Transplantation for the Treatment of Diffuse Large B Cell Lymphoma

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4517-4517
Author(s):  
Mark H. Lee ◽  
Sung-Yong Kim ◽  
Inho Kim ◽  
Seonyang Park ◽  
Yeo-Kyeoung Kim ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Cell Lymphoma ◽  
Survival Rates ◽  
B Cell Lymphoma ◽  
Bulky Disease ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract Abstract 4517 Prognosis in diffuse large B cell lymphoma (DLBCL) is highly associated with the International Prognostic Index (IPI) score, which was proposed to assign prognosis to patients with aggressive non-Hodgkin lymphoma undergoing treatment with doxorubicin-containing chemotherapy. The addition of rituximab to CHOP or CHOP-like regimens has resulted in significant improvements in the overall survival (OS) rate of CD20 positive DLBCL. In addition, the original IPI scoring system has been validated even in patients receiving rituximab-based chemotherapy. However, OS and progression-free survival (PFS) in patients with high-intermediate or high IPI DLBCL were not satisfactory, and the upfront autologous stem cell transplantation (ASCT) was reported to improve the survival rates in these patients subset. Therefore, we retrospectively evaluated the survival rates in patients with DLBCL with CD20+, who were treated with R-CHOP followed by ASCT. We analyzed 40 DLBCL patients who underwent an ASCT, reported to the Korean Blood and Marrow Transplant Registry between 2005 and 2011 by 12 centers. Patients characteristics at diagnosis: 60% male, 5% stage II with bulky disease, 95% stage III or IV, 42.5% bone marrow involvement, 65% high-intermediate or high risk by IPI score. Patients characteristics at ASCT: median age 47 years (range, 23–66) and 82.5% of patients received ≥6 cycles of R-CHOP. Response to R-CHOP: 62.5% CR and 37.5% PR. 17.5% of patients received involved field radiotherapy prior to ASCT for bulky disease or residual lymphoma. Disease status at ASCT: 72.5% CR and 27.5% PR. Median time from diagnosis to ASCT was 7.85 months (range, 4.4–16.1). Median follow-up period from diagnosis was 36.2 months (range, 6.3–84.8). 2-year estimates of PFS, OS and relapse from diagnosis were 73.8%, 86.4% and 24.3%, respectively. 5-year estimates of PFS, OS and relapse were 70.8%, 68.3% and 27.4%, respectively. 3-year estimates of PFS and OS according to IPI score were not significantly different among 4 risk groups (P=0.890 and P=0.855, respectively). The upfront ASCT following R-CHOP induction therapy may improve survival for patients with advanced high risk DLBCL. Prospective evaluation of the treatment outcome of R-CHOP followed by ASCT is needed for high risk DLBCL on a large scale. Disclosures: No relevant conflicts of interest to declare.

Nonimmunoglobulin (non-Ig)/BCL6gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6

Blood ◽  
2000 ◽  
Vol 96 (8) ◽  
pp. 2907-2909 ◽  
Author(s):  
Takashi Akasaka ◽  
Chiyoko Ueda ◽  
Masayuki Kurata ◽  
Hiroshi Akasaka ◽  
Hirohiko Yamabe ◽  
...  
Keyword(s):  
Overall Survival ◽  
B Cell ◽  
Cell Lymphoma ◽  
Survival Rates ◽  
Chromosomal Translocation ◽  
B Cell Lymphoma ◽  
Prognostic Indicator ◽  
Long Distance ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Chromosomal translocation involving the BCL6 gene affects not only immunoglobulin (Ig) genes but also a number of non-Ig genes as partners. The molecular anatomy of the BCL6 gene rearrangements in 39 cases with diffuse large B-cell lymphoma (DLBCL) by long-distance polymerase chain reaction–based assays was determined. The results showed that Iggenes were affected in 21 cases; non-Ig genes, 15 cases; a deletion of more than a 1-kb segment, 2 cases; and a point mutation, 1 case. Comparative studies between the 21 cases withIg gene partners and the 17 cases with non-Iggene partners, including 2 cases with the deletion, showed that the overall survival of the latter group of patients was significantly inferior to that of the former (P = .0440), and the estimated 2-year overall survival rates were 58.3% vs 17.6% (P = .005). Non-Ig/BCL6 fusion is a poor prognostic indicator of DLBCL, and DLBCL with BCL6translocation could be subclassified according to the individual partner locus and/or gene.

Role of radiation (RT) in primary mediastinal large B-cell lymphoma (PMBCL): An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8562-8562
Author(s):  
Smith Giri ◽  
Vijaya Raj Bhatt ◽  
Ranjan Pathak ◽  
Gregory Bociek ◽  
Julie Vose ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Seer Database ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
End Results

scholarly journals Primary Extranodal Diffuse Large B-Cell Lymphoma of the Prostate: A Case Report

2017 ◽  
Vol 10 (1) ◽  
pp. 199-204 ◽  
Author(s):  
Daniel E. Ezekwudo ◽  
Foluso Ogunleye ◽  
Bolanle Gbadamosi ◽  
LeAnn M. Blankenship ◽  
Michael Kinoyan ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Prostate Gland ◽  
B Cell Lymphoma ◽  
Treatment Modalities ◽  
Rare Presentation ◽  
Large B Cell Lymphoma ◽  
Low Incidence ◽  
Large B Cell ◽  
Therapy Treatment

We report a case of primary diffuse large B-cell lymphoma of the prostate in a 54-year-old Caucasian male who presented with urinary retention and benign prostatic hyperplasia. We discuss the rare presentation of this disease and its clinicopathologic features and review the literature for up-to-date information on the diagnosis and clinical management. Despite the low incidence of lymphoma involving the prostate gland, it should always be considered as part of the differential diagnosis in cases of prostate gland enlargement with urinary tract obstructive symptoms resistant to medical therapy. Treatment modalities for this rare disease are also discussed.

scholarly journals Establishment of a Nomogram for Patients with Primary Mediastinal Large B-Cell Lymphoma Based on the SEER Database and Validation of Real-World Data

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1341-1341
Author(s):  
Hua Wang ◽  
Guanjun Chen ◽  
Bibo Fu
Keyword(s):  
Prognostic Factors ◽  
B Cell ◽  
Cell Lymphoma ◽  
External Validation ◽  
B Cell Lymphoma ◽  
Seer Database ◽  
Real World Data ◽  
Decision Curve Analysis ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract Background Primary mediastinal large B-cell lymphoma (PMBCL) is a rare disease with the majority of patients being rapidly progressive anterior mediastinal large tumors. Due to the rarity of PMBCL, information on the incidence, clinical features, prognostic factors and models of PMBCL is limited. The present study is one of the largest studies on the incidence and prognostic factors of PMBCL and is the first to establish a nomogram model of PMBCL and validate it with real-world data. We also compared the newly established Nomogram with the existing IPI prognostic model. We believe that our findings can help clinicians to quickly and accurately assess the predicted survival of patients and help them to perform individualized risk stratification of patients. Methods Based on data from the Surveillance, Epidemiology and End Results (SEER) database, 797 patients diagnosed with PMBCL were enrolled in this study. The 797 patients were randomly divided into training and internal validation groups in a 7:3 ratio, and 116 patients diagnosed with PMBCL were included in the external validation group based on data from the Sun Yat-sen University Cancer Center and the First Affiliated Hospital of Guangzhou Medical University. Independent prognostic factors were screened by Cox regression analysis. R-coding was used to construct nomograms predicting overall survival (OS). Discriminations and corrections of the new model were assessed using the consistency index (C-index), subject operating characteristic curves (ROC) and calibration curves, and compared with the conventional international prognostic index (IPI) using decision curve analysis (DCA) to assess its accuracy and benefit. Results From 2001 to 2016, the incidence of primary mediastinal large B-cell lymphoma showed a relatively stable increasing trend with an APC of 11.8% (95% confidence interval 8.8-14.0, P<0.05), and this trend was more pronounced in the female population. Multivariate models showed that age and Ann arbor staging were significantly associated with OS, while the variable of extra-nodal invasion was included in the modeling based on clinical experience. In the training cohort, the C-index of the nomogram for OS was 0.712. the C-index for the internal and external validation cohorts was 0.667 and 0.690, respectively. The calibration curve also showed high predictive accuracy. The C-index and ROC curves of nomogram showed better results compared to IPI scores, and also yielded better net gains in decision curve analysis. Conclusion In summary, we successfully established a validated nomogram for predicting OS in patients with PMBCL, which can help clinicians to select appropriate individualized treatment for their patients. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document